Abstract:Bladder cancer is the tenth most prevalent malignancy worldwide, with a significant mortality burden. Urothelial carcinoma (UC) is the most common histological subtype, and treatment options are guided by whether the disease is muscle-invasive (MIBC) or non-muscle-invasive (NMIBC), with subsequent risk group stratification. The growing popularity of immune checkpoint inhibitors (ICIs) to treat MIBC and NMIBC as either monotherapy or combined with intravesical agents, may radically change the treatment paradigm of UC. Current treatments for NMBIC includes intravesical chemotherapy after trans-urethral resection of the bladder tumour, intravesical bacillus Calmette-Guerin (BCG) or radical cystectomy. Cisplatin-based chemotherapy is widely regarded as the first-line treatment for metastatic UC due to its beneficial response and survival rates when compared to alternative therapies. However, up to 70 % of metastatic UC patients are ineligible, and the prognosis of these patients remains poor, with a median survival of 13-16 months. For NMIBC and MIBC, ICIs provide a promising alternative for cisplatin-ineligible patients. In UC, ICIs including atezolizumab, nivolumab, avelumab, and pembrolizumab are Food and Drug Administration (FDA)-approved for monotherapy, and have demonstrated promising results, particularly in those who cannot receive cisplatin-based chemotherapy, and as a second-line treatment option for recurrent UC following platinum-based chemotherapy. It is important to consider that some patients may experience adverse events (AEs) with limited clinical benefit. Infusion-related reactions and immune-mediated AEs (imAEs) such as colitis, endocrinopathies, hepatitis, pneumonitis, interstitial lung disease, renal dysfunction, nephritis, cutaneous and neurological toxicities must be monitored for. Currently, there is no clear consensus on the role of a 'two-year stopping rule' in reducing the risk of imAEs, with further research on the optimal treatment duration of ICIs required. With increased ICI use, vigilance regarding their side effects is imperative. This review aims to provide an updated overview of ICI toxicities in bladder cancer, to assist clinicians in their therapeutic decision-making, with consideration of patient characteristics and the clinical context.

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma

An overview of immune checkpoint inhibitor toxicities in bladder cancer

Effectiveness and Safety of Immune Checkpoint Inhibitor Monotherapy in Advanced Upper Tract Urothelial Carcinoma: A Multicenter, Retrospective, Real‐world Study

The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma

A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines

Immunotherapy with or Without Targeted Therapy for Metastatic Upper Tract Urothelial Carcinoma: Case Report and Literature Review.

Progress in immune checkpoint inhibitor-based combined regimens in the treatment of metastatic urothelial carcinoma

Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors

Toxicity of tumor immune checkpoint inhibitors-more attention should be paid.

Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review

Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis

Management and nursing strategies for different patterns of adverse events in patients with urological cancer treated with immune checkpoint inhibitors

Efficacy and Adverse Events of PD-1 Inhibitors in Patients with Advanced Urothelial Carcinoma from a Real-World Experience

Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review

&Lt;p>adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma</p>

The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies

Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions

Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma

[Adverse events of immune checkpoint inhibitors]

Toxicity-Induced Discontinuation of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer: 6-Year Experience from a Specialized Uro-Oncology Center

[Managing the Adverse Effects Related to Immune Checkpoint Inhibitors]